MET and non-small cell lung carcinoma: Of note, MET amplification often represents a mechanism to sustain secondary resistances to epidermal growth factor receptor (EGFR) targeting agents in Non-Small-Cell Lung Cancer (NSCLC) and colorectal cancer (CRC) [22,23].